Open Orphan (ORPH ) spin out Poolbeg Pharma (POLB ) listed on AIM this morning raising £25m. In this first Company interview Chairman, Cathal Friel, and CEO, Jeremy Skillington discusses the Company's ready made assets focusing on unmet clinical needs including their lead asset in severe infuenza and the large data set ready for analysis. They go on to discuss the Company's plans to partner with large pharma and the speed and at which they expect growth.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
